Inhibikase Therapeutics
IKT · NASDAQ
$1.71−$0.05 (−2.84%)TodayMarket closed ·
Prev close $1.76
About IKT
- Employees
- 35
- Headquarters
- Wilmington, Delaware
- Listed
- Dec 23, 2020
- Sector
- Health Care
- Industry
- Biotechnology
- Website
- inhibikase.com
Leadership
| Name | Title | Since |
|---|---|---|
| Amit Munshi | — | — |
| Christopher Cabell | — | — |
| Mark Iwicki | — | 2025 |
| David Mcintyre | — | — |
| John Adams | — | — |
| Timothy Pigot | — | — |
| Vincent Aurentz | — | — |
| Roberto Bellini | — | — |
| Dennis Berman | — | — |
| David Canner | — | — |
| Roy Freeman | — | — |
| Arvind Kush | — | — |
| Mike Moyer | — | 2024 |
Suppliers and customers
Price correlation is over one year: 1 means the stocks move together, -1 opposite
| Company | Relationship | Correlation |
|---|---|---|
| WuXi AppTec Co H | Supplier and customer | 0.79 |
| Apex Innovative Sciences, Inc. | Supplier | — |
| Celerion, Inc. | Supplier | — |
| Clintrex Research Corp. | Supplier | — |
| Cognitive Research Corp. | Supplier | — |
| EMORY UNIVERSITY | Supplier and customer | — |
| Michael J. Fox Foundation for Parkinson's Research | Customer | — |
| Pace Analytical Services LLC | Supplier and customer | — |
| United States | Customer | — |
| Duke University | Supplier and customer | — |
Similar companies
Companies in the same industry as Inhibikase Therapeutics
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.